wpusername6013

SDK Therapeutics Announces FDA Orphan Drug Designation Granted to SDK001 (Oral Solution of Arsenic Trioxide) for Treatment of Acute Promyelocytic Leukemia

On: December 17, 2024

The FDA Office of Orphan Products Development has granted SDK001 (oral solution of Arsenic Trioxide) Orphan Drug Designation (ODD) for the treatment of Acute Promyelocytic Leukemia (APL).Read More →

SDK Therapeutics Acquires Exclusive Right to Develop and Commercialize Arsenic Trioxide Oral Solution for North America and Europe

By: wpusername6013

On: June 15, 2024

In: Media, Uncategorized

Biotechnology company focused on developing and commercializing medicines in hematology, oncology, and rare diseases to improve the life of patientsRead More →

CONTACT:

wpusername6013